Teva to produce coronavirus drug under Pfizer patent

The Israeli pharmaceutical concern Teva has signed an agreement on the production of the Paxlovoid coronavirus drug under a Pfizer patent as part of a global UN project.

In addition to Teva, another 34 pharmaceutical companies from Asia, the Middle East, Latin America, the Caribbean and Eastern Europe will take part in the project for the production of the drug or ingredients for it.

Production under the Pfizer patent will be for the world’s poorest countries, which cannot afford to buy the drug at the price it is shipped to developed countries. Deliveries are expected to start in 2023.

By Editor

Leave a Reply